vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Lumentum Holdings Inc. (LITE). Click either name above to swap in a different company.

Lumentum Holdings Inc. is the larger business by last-quarter revenue ($665.5M vs $487.7M, roughly 1.4× CLOVER HEALTH INVESTMENTS, CORP.). Lumentum Holdings Inc. runs the higher net margin — 11.8% vs -10.1%, a 21.9% gap on every dollar of revenue. On growth, Lumentum Holdings Inc. posted the faster year-over-year revenue change (65.5% vs 44.7%). Lumentum Holdings Inc. produced more free cash flow last quarter ($43.1M vs $-69.0M). Over the past eight quarters, Lumentum Holdings Inc.'s revenue compounded faster (34.8% CAGR vs 18.6%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

JDS Uniphase Corporation (JDSU) was an American company that designed and manufactured products for optical communications networks, communications test and measurement equipment, lasers, optical solutions for authentication and decorative applications, and other custom optics. It was headquartered in Milpitas, California. In August 2015, JDSU split into two different companies – Viavi Solutions and Lumentum Holdings.

CLOV vs LITE — Head-to-Head

Bigger by revenue
LITE
LITE
1.4× larger
LITE
$665.5M
$487.7M
CLOV
Growing faster (revenue YoY)
LITE
LITE
+20.7% gap
LITE
65.5%
44.7%
CLOV
Higher net margin
LITE
LITE
21.9% more per $
LITE
11.8%
-10.1%
CLOV
More free cash flow
LITE
LITE
$112.1M more FCF
LITE
$43.1M
$-69.0M
CLOV
Faster 2-yr revenue CAGR
LITE
LITE
Annualised
LITE
34.8%
18.6%
CLOV

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
CLOV
CLOV
LITE
LITE
Revenue
$487.7M
$665.5M
Net Profit
$-49.3M
$78.2M
Gross Margin
36.1%
Operating Margin
-10.1%
9.7%
Net Margin
-10.1%
11.8%
Revenue YoY
44.7%
65.5%
Net Profit YoY
-123.2%
228.4%
EPS (diluted)
$0.89

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
LITE
LITE
Q4 25
$487.7M
$665.5M
Q3 25
$496.6M
$533.8M
Q2 25
$477.6M
$480.7M
Q1 25
$462.3M
$425.2M
Q4 24
$337.0M
$402.2M
Q3 24
$331.0M
$336.9M
Q2 24
$356.3M
$308.3M
Q1 24
$346.9M
$366.5M
Net Profit
CLOV
CLOV
LITE
LITE
Q4 25
$-49.3M
$78.2M
Q3 25
$-24.4M
$4.2M
Q2 25
$-10.6M
$213.3M
Q1 25
$-1.3M
$-44.1M
Q4 24
$-22.1M
$-60.9M
Q3 24
$-9.2M
$-82.4M
Q2 24
$7.4M
$-252.5M
Q1 24
$-19.2M
$-127.0M
Gross Margin
CLOV
CLOV
LITE
LITE
Q4 25
36.1%
Q3 25
34.0%
Q2 25
33.3%
Q1 25
28.8%
Q4 24
24.8%
Q3 24
24.5%
23.1%
Q2 24
30.3%
16.6%
Q1 24
23.6%
16.2%
Operating Margin
CLOV
CLOV
LITE
LITE
Q4 25
-10.1%
9.7%
Q3 25
-4.9%
1.3%
Q2 25
-2.2%
-1.7%
Q1 25
-0.3%
-8.9%
Q4 24
-6.4%
-12.8%
Q3 24
-2.7%
-24.5%
Q2 24
2.0%
-43.3%
Q1 24
-6.5%
-31.3%
Net Margin
CLOV
CLOV
LITE
LITE
Q4 25
-10.1%
11.8%
Q3 25
-4.9%
0.8%
Q2 25
-2.2%
44.4%
Q1 25
-0.3%
-10.4%
Q4 24
-6.6%
-15.1%
Q3 24
-2.8%
-24.5%
Q2 24
2.1%
-81.9%
Q1 24
-5.5%
-34.7%
EPS (diluted)
CLOV
CLOV
LITE
LITE
Q4 25
$0.89
Q3 25
$0.05
Q2 25
$3.10
Q1 25
$-0.64
Q4 24
$-0.88
Q3 24
$-1.21
Q2 24
$-3.75
Q1 24
$-1.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
LITE
LITE
Cash + ST InvestmentsLiquidity on hand
$78.3M
$1.2B
Total DebtLower is stronger
Stockholders' EquityBook value
$308.7M
$846.6M
Total Assets
$541.0M
$4.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
LITE
LITE
Q4 25
$78.3M
$1.2B
Q3 25
$1.1B
Q2 25
$877.1M
Q1 25
$866.7M
Q4 24
$194.5M
$896.7M
Q3 24
$288.0M
$916.1M
Q2 24
$254.8M
$887.0M
Q1 24
$208.3M
$870.9M
Stockholders' Equity
CLOV
CLOV
LITE
LITE
Q4 25
$308.7M
$846.6M
Q3 25
$340.9M
$780.8M
Q2 25
$344.2M
$1.1B
Q1 25
$336.1M
$879.5M
Q4 24
$341.1M
$872.3M
Q3 24
$342.2M
$895.9M
Q2 24
$324.9M
$957.3M
Q1 24
$292.5M
$1.2B
Total Assets
CLOV
CLOV
LITE
LITE
Q4 25
$541.0M
$4.8B
Q3 25
$559.7M
$4.6B
Q2 25
$575.0M
$4.2B
Q1 25
$583.7M
$4.0B
Q4 24
$580.7M
$4.0B
Q3 24
$653.0M
$4.0B
Q2 24
$674.2M
$3.9B
Q1 24
$671.8M
$4.2B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
LITE
LITE
Operating Cash FlowLast quarter
$-66.9M
$126.7M
Free Cash FlowOCF − Capex
$-69.0M
$43.1M
FCF MarginFCF / Revenue
-14.1%
6.5%
Capex IntensityCapex / Revenue
0.4%
12.6%
Cash ConversionOCF / Net Profit
1.62×
TTM Free Cash FlowTrailing 4 quarters
$-69.2M
$-29.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
LITE
LITE
Q4 25
$-66.9M
$126.7M
Q3 25
$12.1M
$57.9M
Q2 25
$5.4M
$64.0M
Q1 25
$-16.3M
$-1.6M
Q4 24
$34.8M
$24.3M
Q3 24
$50.0M
$39.6M
Q2 24
$44.8M
$35.5M
Q1 24
$25.9M
$-7.0M
Free Cash Flow
CLOV
CLOV
LITE
LITE
Q4 25
$-69.0M
$43.1M
Q3 25
$11.4M
$-18.3M
Q2 25
$4.8M
$10.1M
Q1 25
$-16.5M
$-64.4M
Q4 24
$33.3M
$-15.9M
Q3 24
$49.6M
$-34.5M
Q2 24
$44.4M
$10.9M
Q1 24
$25.5M
$-26.6M
FCF Margin
CLOV
CLOV
LITE
LITE
Q4 25
-14.1%
6.5%
Q3 25
2.3%
-3.4%
Q2 25
1.0%
2.1%
Q1 25
-3.6%
-15.1%
Q4 24
9.9%
-4.0%
Q3 24
15.0%
-10.2%
Q2 24
12.5%
3.5%
Q1 24
7.3%
-7.3%
Capex Intensity
CLOV
CLOV
LITE
LITE
Q4 25
0.4%
12.6%
Q3 25
0.1%
14.3%
Q2 25
0.1%
11.2%
Q1 25
0.0%
14.8%
Q4 24
0.5%
10.0%
Q3 24
0.1%
22.0%
Q2 24
0.1%
8.0%
Q1 24
0.1%
5.3%
Cash Conversion
CLOV
CLOV
LITE
LITE
Q4 25
1.62×
Q3 25
13.79×
Q2 25
0.30×
Q1 25
Q4 24
Q3 24
Q2 24
6.04×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLOV
CLOV

Segment breakdown not available.

LITE
LITE

Components$443.7M67%
Systems$221.8M33%

Related Comparisons